3-Benzenesulphonylamino-3-{3-[3-(4, 5-dihydro-1H-imidazol-2-ylamino)-phenylsulphonylamino]-phenyl}-propionic acid | 283612-54-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Benzenesulphonylamino-3-{3-[3-(4, 5-dihydro-1H-imidazol-2-ylamino)-phenylsulphonylamino]-phenyl}-propionic acid
• 英文别名: 3-(benzenesulfonamido)-3-[3-[[3-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]sulfonylamino]phenyl]propanoic acid
• CAS: 283612-54-4
• 化学式: C₂₄H₂₅N₅O₆S₂
• 分子量: 543.624
• InChiKey: BWWVUOQTHGGVAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  183
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
  申请人：Bayer Aktiengesellschaft

  公开号：EP1147079A2

  公开（公告）日：2001-10-24
• US6291503B1
  申请人：——

  公开号：US6291503B1

  公开（公告）日：2001-09-18
• [EN] beta -PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS<br/>[FR] DERIVES DE beta -PHENYLALANINE CONSTITUANT DES ANTAGONISTES DE L'INTEGRINE
  申请人：BAYER AG

  公开号：WO2000041469A2

  公开（公告）日：2000-07-20

  The present invention relates to compounds of general formula (1), wherein R4 is -SO¿2?R?4', -COOR4', -COR4', -CONR4'¿2 or -CSNR4'2; R4' is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; R4' is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; L is a sulphonamide, amide, ether, ester, keto, urea, thioether, sulphoxide or sulphone unit optionally extended by one or two methylene groups; and X is N, O or S; and their physiologically acceptable salts and stereoisomers. The present invention furthermore relates to a process for the preparation of the compounds of formula (1), a pharmaceutical composition containing at least one of these compounds, and the use of compounds of formula (1) for the production of a pharmaceutical composition having integrin-antagonistic action and in particular for the inhibition of angiogenesis and/or for the therapy and prophylaxis of cancer, osteolytic diseases such as osteoporosis, arteriosclerosis, restenosis and ophthalmic disorders.